Concepts (95)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Rare Diseases | 1 | 2024 | 185 | 0.830 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2020 | 66 | 0.700 |
Why?
|
| Neoplasms | 4 | 2025 | 2758 | 0.690 |
Why?
|
| Immunologic Factors | 1 | 2020 | 179 | 0.640 |
Why?
|
| Immunotherapy, Adoptive | 6 | 2025 | 801 | 0.580 |
Why?
|
| Receptors, Antigen, T-Cell | 3 | 2020 | 477 | 0.560 |
Why?
|
| Immunotherapy | 1 | 2020 | 653 | 0.500 |
Why?
|
| Neuroblastoma | 1 | 2020 | 509 | 0.500 |
Why?
|
| Receptor, ErbB-2 | 3 | 2024 | 494 | 0.420 |
Why?
|
| Sarcoma | 2 | 2024 | 194 | 0.350 |
Why?
|
| T-Lymphocytes | 5 | 2024 | 1677 | 0.330 |
Why?
|
| Paclitaxel | 1 | 2014 | 120 | 0.220 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2014 | 101 | 0.220 |
Why?
|
| Medical Oncology | 1 | 2024 | 214 | 0.210 |
Why?
|
| Clinical Decision-Making | 1 | 2024 | 265 | 0.210 |
Why?
|
| Sarcoma, Kaposi | 1 | 2014 | 120 | 0.200 |
Why?
|
| Child | 10 | 2025 | 24237 | 0.200 |
Why?
|
| Liposarcoma | 1 | 2021 | 21 | 0.190 |
Why?
|
| Hematologic Neoplasms | 1 | 2025 | 286 | 0.190 |
Why?
|
| Lymphoma | 1 | 2024 | 321 | 0.180 |
Why?
|
| Leukemia | 1 | 2024 | 375 | 0.180 |
Why?
|
| Muscle Neoplasms | 1 | 2020 | 21 | 0.180 |
Why?
|
| Biomarkers, Tumor | 2 | 2019 | 1430 | 0.170 |
Why?
|
| Leukemia, B-Cell | 1 | 2020 | 26 | 0.170 |
Why?
|
| Hyperbilirubinemia | 1 | 2019 | 41 | 0.170 |
Why?
|
| Antigens, CD19 | 1 | 2020 | 177 | 0.160 |
Why?
|
| Rhabdomyosarcoma | 1 | 2020 | 200 | 0.140 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2020 | 1117 | 0.140 |
Why?
|
| Interleukin-13 Receptor alpha2 Subunit | 1 | 2016 | 20 | 0.130 |
Why?
|
| Tumor Escape | 1 | 2016 | 61 | 0.130 |
Why?
|
| Pediatrics | 1 | 2024 | 1139 | 0.120 |
Why?
|
| Humans | 14 | 2025 | 123166 | 0.120 |
Why?
|
| Lymphocyte Depletion | 2 | 2024 | 124 | 0.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 1227 | 0.100 |
Why?
|
| Glioblastoma | 1 | 2016 | 334 | 0.100 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 804 | 0.100 |
Why?
|
| Tumor Microenvironment | 1 | 2016 | 530 | 0.100 |
Why?
|
| Registries | 1 | 2019 | 1392 | 0.100 |
Why?
|
| Prognosis | 4 | 2025 | 4507 | 0.100 |
Why?
|
| HIV Infections | 1 | 2014 | 1874 | 0.100 |
Why?
|
| Melanoma | 1 | 2019 | 824 | 0.100 |
Why?
|
| Skin Neoplasms | 1 | 2019 | 795 | 0.100 |
Why?
|
| Infant | 3 | 2025 | 12348 | 0.100 |
Why?
|
| United States | 1 | 2024 | 10631 | 0.080 |
Why?
|
| Follow-Up Studies | 3 | 2025 | 5047 | 0.070 |
Why?
|
| Brain Neoplasms | 1 | 2016 | 1235 | 0.070 |
Why?
|
| Transgenes | 2 | 2020 | 334 | 0.070 |
Why?
|
| Female | 6 | 2025 | 65499 | 0.070 |
Why?
|
| Treatment Outcome | 4 | 2024 | 12129 | 0.070 |
Why?
|
| Child, Preschool | 4 | 2025 | 13887 | 0.070 |
Why?
|
| Antigens, Neoplasm | 2 | 2020 | 387 | 0.060 |
Why?
|
| Male | 7 | 2025 | 60079 | 0.060 |
Why?
|
| Adult | 5 | 2024 | 29061 | 0.060 |
Why?
|
| Protein Binding | 2 | 2020 | 1741 | 0.060 |
Why?
|
| Vidarabine | 1 | 2024 | 79 | 0.060 |
Why?
|
| Adolescent | 4 | 2025 | 19103 | 0.060 |
Why?
|
| Radiography, Thoracic | 1 | 2014 | 156 | 0.050 |
Why?
|
| Young Adult | 3 | 2024 | 8863 | 0.050 |
Why?
|
| Neutropenia | 1 | 2024 | 202 | 0.050 |
Why?
|
| Thrombocytopenia | 1 | 2024 | 228 | 0.050 |
Why?
|
| Cyclophosphamide | 1 | 2024 | 419 | 0.050 |
Why?
|
| Incidence | 2 | 2019 | 3047 | 0.050 |
Why?
|
| Cell Line, Tumor | 2 | 2020 | 3273 | 0.050 |
Why?
|
| Texas | 2 | 2019 | 3555 | 0.040 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2020 | 57 | 0.040 |
Why?
|
| Recurrence | 1 | 2014 | 1422 | 0.040 |
Why?
|
| Transplantation, Autologous | 1 | 2020 | 296 | 0.040 |
Why?
|
| Remission Induction | 1 | 2020 | 300 | 0.040 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2020 | 262 | 0.040 |
Why?
|
| Transduction, Genetic | 1 | 2020 | 290 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2020 | 567 | 0.040 |
Why?
|
| Bone Marrow | 1 | 2020 | 323 | 0.040 |
Why?
|
| SEER Program | 1 | 2019 | 194 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2020 | 877 | 0.030 |
Why?
|
| Biopsy | 1 | 2020 | 1237 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2025 | 16021 | 0.030 |
Why?
|
| Aged | 2 | 2024 | 19080 | 0.030 |
Why?
|
| Interleukin-13 | 1 | 2016 | 96 | 0.030 |
Why?
|
| Protein Multimerization | 1 | 2016 | 122 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2016 | 369 | 0.030 |
Why?
|
| Gene Expression | 1 | 2020 | 1566 | 0.030 |
Why?
|
| Risk Factors | 2 | 2019 | 10010 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2016 | 571 | 0.030 |
Why?
|
| Middle Aged | 2 | 2024 | 25994 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2020 | 2388 | 0.030 |
Why?
|
| Cytokines | 1 | 2020 | 1285 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2016 | 677 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2024 | 6033 | 0.030 |
Why?
|
| Cardiovascular Diseases | 1 | 2025 | 1863 | 0.030 |
Why?
|
| Biomarkers | 1 | 2020 | 2946 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2020 | 4271 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 1661 | 0.020 |
Why?
|
| Animals | 2 | 2020 | 33746 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2019 | 8108 | 0.020 |
Why?
|
| Mice | 1 | 2016 | 17491 | 0.010 |
Why?
|